Skip to main content

Ongoing FDAEvent 99689 (17 days ago)

Pipeline Flex Embolization Device with Shield Technology

The Pipeline Flex Embolization Device with Shield Technology has incorrect label dimensions, being 2.50 mm instead of 3.00 mm.

Moderate risk

Using it may cause temporary or medically reversible health problems. Serious harm is unlikely.

FDA Class II recall · How risk is rated

What to do

What happened

Micro Therapeutics, Inc. recalled the Pipeline Flex Embolization Device with Shield Technology because the unit in packaging was 2.50 mm in diameter instead of the supposed 3.00 mm. The company began the recall on June 25, 2026, and the FDA added it to the Enforcement Report on September 28, 2026.

Summary by Recall Canary from the FDA notice.

What to do

We don't have product-specific instructions for this recall. FDA's general advice for medical device recalls:

  1. A device recall doesn't always mean you must stop using it: it may need to be checked, adjusted or fixed.
  2. Talk to your health care provider before you stop using it.

Is yours affected?

Compare the details below with your product and check the FDA notice to confirm whether it is affected.

  1. Product details

    Pipeline Flex Embolization Device with Shield Technology REF PED2-300-12 UDI-DI code: 00763000448806 he Pipeline Flex Embolization Device with Shield Technology consists of a permanent implant combined with a guidewire based delivery system. The Pipeline Flex Embolization Device with Shield Technology implant

    UDI-DI
    • 00763000448806

Details

Company began the recall
Sold in

U.S. Nationwide distribution in the states of Georgia and Texas.

Event ID
99689
Recall No.
Z-3326-2026
Company
Micro Therapeutics, Inc.Irvine, California
  1. Company began the recall

  2. Added to FDA's Enforcement Report · Classified by FDA

  3. Listed on Recall Canary

  4. Summary updated

  5. In FDA's weekly enforcement report

All recalls from Micro Therapeutics, Inc.

Summary by Recall Canary, written with AI · summary updated Oct 2, 2026 · primary source: U.S. Food and Drug Administration